InfuSystem Holdings (INFU) Q1 2025 Earnings Call May 08, 2025 09:00 AM ET Speaker0 Good day, and welcome to the InfuSystem Holdings, Inc. Reports First Quarter twenty twenty five Financial Results Conference Call. All participants will be in listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press then 1 on your touch tone phone. To ...

Financial Data and Key Metrics Changes - The company achieved record total net revenue of $52.6 million for the first quarter, with MACI revenue of $46.3 million, Epicel revenue of $5 million, and NexoBrid revenue of $1.3 million [13] - MACI revenue grew by 15% year-over-year, which adjusts to approximately 17% growth when accounting for one fewer selling day in the quarter [14] - NexoBrid revenue increased by 207% year-over-year and 31% sequentially [14] - The net loss for the quarter was $11.2 million, or $0.23 per share, with non-GAAP adjusted EBITDA of $3.2 million, representing 6% of net revenue [16] Business Line Data and Key Metrics Changes - MACI had a strong quarter with record revenue exceeding $46 million, driven by strong underlying fundamentals and a growing surgeon customer base [6][5] - NexoBrid's revenue growth was significant, with over 200% increase compared to the previous year, indicating strong market penetration [10] - Epicel revenue was lower than anticipated due to a high percentage of canceled cases, but there was a strong start to the second quarter with graft volumes exceeding the first quarter [11][12] Market Data and Key Metrics Changes - The company expects total revenue growth of 22% to 25% for the second quarter, with MACI revenue projected to be approximately $54 million [18] - The addressable market for MACI is estimated at 60,000 patients annually, with significant opportunities in femoral condyle and trochlear defects [26][20] Company Strategy and Development Direction - The company is advancing the MACI Ankle Development Program and plans to initiate a Phase III clinical study in the second half of the year, which represents a substantial long-term growth driver [20] - The company plans to expand its MACI sales force in the second half of the year to support growth driven by MACI Arthro [10][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about strong second quarter performance based on positive trends observed in the first quarter, reaffirming full-year revenue guidance of 20% to 23% growth [5][17] - The company anticipates minimal impact from tariffs due to its domestic manufacturing and significant safety stock of materials [17] Other Important Information - The company generated $6.6 million in operating cash flow and ended the quarter with approximately $162 million in cash and no debt [16] - Management raised profitability guidance for the year, expecting gross margins to reach 75% and adjusted EBITDA margins to reach 26% [18] Q&A Session Summary Question: Can you discuss the market opportunity for femoral condyle and trochlear specifically? - Management indicated that the MACI Arthro instruments are designed for femoral condyle defects, which represent a significant portion of the addressable market, and there is potential for treating trochlear defects as well [26][27] Question: How do you see seasonality and pacing for MACI in the second half of the year? - Management noted that while MACI typically follows a prescriptive pattern, strong leading indicators suggest potential for stronger growth in the second half of the year [32][33] Question: What is the contribution of MACI Arthro to first quarter numbers? - Management acknowledged that while there was some incremental impact from MACI Arthro, the full effect is expected to be seen in the second half of the year [38][40] Question: How have recent trade war headlines impacted international views on MACI? - Management stated that they are evaluating potential for MACI outside the U.S. but will consider tariffs and trade impacts before making decisions [92] Question: Can you provide insights on conversion rates for MACI Arthro procedures? - Management indicated that it is early to assess conversion rates, but they expect higher rates over time due to the less invasive nature of the procedure [57][66] Question: What are the dynamics of cross-selling opportunities between Epicel and NexoBrid? - Management confirmed that they are seeing biopsies from previously dormant accounts and expect this trend to continue as they cross-sell products [61] Question: Can you elaborate on the sales force expansion plans? - Management indicated that while the expansion is not full-scale this year, they are preparing to add resources to support expected growth [80][81]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $36.3 million, down 26% year over year and down 18% in constant currency, primarily due to lower corporate sales in Egypt and currency devaluation [19][36]. - Adjusted EBITDA loss was $15.7 million in Q1 2025, compared to a loss of $4.3 million in Q1 2024 [19][41]. - Loss before income tax was $16.5 million, a significant improvement from $39.6 million in the same period last year [19][41]. Business Line Data and Key Metrics Changes - Marketplace revenue for Q1 was $18.1 million, down 30% year over year [36]. - Revenue from first-party sales was $17.8 million, down 21% year over year [36]. - Fulfillment expense per order decreased to $2.07, down 14% year over year, indicating improved efficiency [39][11]. Market Data and Key Metrics Changes - GMV declined 11% year over year, primarily due to currency headwinds and lower corporate sales, particularly in Egypt [16][19]. - Excluding corporate sales, GMV would have grown 10% year over year, highlighting strengths in the consumer business [16][19]. - Physical Goods orders grew 21% year over year, driven by strong demand [15][19]. Company Strategy and Development Direction - The company aims to reduce losses, drive efficiency, and deliver measurable financial improvements, with a focus on margin expansion and financial discipline [6][7]. - Jumia is expanding its logistics network to monetize its infrastructure beyond the core marketplace, which is expected to enhance cost efficiency [28][62]. - The company is targeting profitability by 2027, with a loss before income tax forecasted to improve significantly in 2026 [9][45]. Management's Comments on Operating Environment and Future Outlook - Management noted that while currency headwinds have impacted profitability, they expect to see improved growth trends moving forward as these effects have lapped [18][32]. - The company remains confident in its strategy and believes it is well-positioned to capture supply from Asia as global trade dynamics shift [32][56]. - Management emphasized the importance of operational discipline and cost management in achieving sustainable growth [43][33]. Other Important Information - The company has reduced its total headcount by about 3% as part of its cost control measures [11]. - Jumia's liquidity position at the end of Q1 was $110.7 million, including cash and cash equivalents [42]. - The company remains debt-free, with borrowing related solely to lease liabilities [43]. Q&A Session Summary Question: Can you explain the relationship between orders and GMV? - Corporate sales are typically high-value orders that generate significant GMV with few orders, leading to a disconnect when corporate sales decrease [49]. Question: How should we think about cash use from inventory levels? - A significant part of cash burn is due to increased working capital for inventory ahead of major campaigns, but lower impacts are expected in the coming quarters [54]. Question: Have you seen an uptick in supply from Asia? - There has been a strong trend in item sales from international vendors, particularly from China, with a 61% increase in gross items sold [55]. Question: What is the monetization strategy for the Jumia delivery business? - The delivery business is designed to be higher margin and lower volume compared to marketplace revenue, with profitability from day one [90]. Question: How significant is the deliveries business to revenue for Ivory Coast? - The deliveries business is profitable but lower than marketplace revenues, with potential for further scaling [93].

Krispy Kreme (DNUT) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Alexandre Eldredge - Senior Manager of IRJoshua Charlesworth - President & CEOJeremiah Ashukian - EVP & CFORahul Krotthapalli - Vice President - Equity ResearchBill Chappell - Managing Director Conference Call Participants Daniel Guglielmo - Equity Research AnalystNone - AnalystAndrew Wolf - SVP & Senior Research Analyst Operator Hello, everyone, and thanks for standing by. My name is Ian, and I will be your conference o ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $36.3 million, down 26% year over year and down 18% in constant currency, primarily due to lower corporate sales in Egypt and currency devaluation [33][34] - Adjusted EBITDA loss was $15.7 million in Q1 2025 compared to a loss of $4.3 million in Q1 2024, while loss before income tax improved to $16.5 million from $39.6 million year over year [17][39] - Cash burn for the quarter was $23.2 million, including $8 million in working capital, with expectations to significantly reduce cash burn in upcoming quarters [13][40] Business Line Data and Key Metrics Changes - Physical Goods orders grew 21% year over year, with quarterly active customers ordering Physical Goods increasing by 15% year over year, marking the highest growth rates in two years [14][15] - GMV declined 11% year over year, primarily due to currency headwinds and lower corporate sales, but would have grown 10% year over year excluding corporate sales [15][16] - Fulfillment expense per order decreased to $2.07, down 14% year over year, reflecting improved efficiency [10][37] Market Data and Key Metrics Changes - In Q1 2025, Ivory Coast, Nigeria, Kenya, and Egypt represented approximately 26%, 22%, 15%, and 10% of company GMV respectively, with other markets contributing 27% [20] - Nigeria saw Physical Goods orders grow by 22% and GMV increase by 18% year over year, while Kenya experienced a 36% growth in Physical Goods orders [21][22] - Egypt's Physical Goods orders were down 15% year over year, with GMV decreasing 69% in USD, primarily due to a decline in corporate sales [23] Company Strategy and Development Direction - The company aims to reduce losses, drive efficiency, and deliver measurable financial improvements, with a focus on margin expansion and financial discipline [5][6] - A comprehensive restructuring plan was launched in early 2024 to address operational challenges, particularly in Egypt [23] - The company is expanding its logistics platform to monetize its infrastructure beyond the core marketplace, targeting third-party sellers and social commerce merchants [25][60] Management's Comments on Operating Environment and Future Outlook - Management noted that while currency headwinds have impacted profitability, they expect a cleaner year-over-year comparison moving forward as these effects have lapped [16][34] - The company anticipates continued momentum in Q2 2025, with expectations for Physical Goods orders growth in the range of 20% to 25% [43][44] - Management remains confident in achieving profitability by Q4 2026 and full-year profitability in 2027, driven by cost management and volume increases [44][72] Other Important Information - The company has renegotiated or terminated several key software and hosting contracts, expecting significant cost savings starting in the second half of 2025 [11][38] - The liquidity position at the end of Q1 2025 was $110.7 million, with no financial debt, reflecting a strong cash position [40][41] Q&A Session Summary Question: Can you explain the relationship between orders and GMV? - Management clarified that corporate sales, which are high-value orders, significantly impact GMV, leading to a disconnect between orders and GMV [47][48] Question: How should we think about cash use from inventory levels? - Management indicated that increased working capital was primarily used to build up inventories ahead of significant commercial events, and they anticipate lower impacts from working capital in the coming quarters [51][52] Question: Have you seen an uptick in supply from Asia? - Management confirmed an uptick in international vendor sales, particularly from China, and expects this trend to continue as access to supply improves [53][54] Question: How do you plan to approach marketing as fundamentals improve? - Management stated that they are now in a position to be more aggressive with marketing in markets where fundamentals are strong, such as Nigeria [55][56] Question: What is the timeline for the logistics expansion? - Management explained that the logistics network is now stable enough to monetize outside the marketplace, with no negative impact on margins expected [60][62] Question: What is the visibility on 2026 guidance? - Management indicated that they expect to reach breakeven by Q4 2026, driven by growth and cost management efforts [72]

Financial Data and Key Metrics Changes - The company achieved record total net revenue of $52.6 million for Q1 2025, with MACI revenue of $46.3 million, Epicel revenue of $5 million, and NexoBrid revenue of $1.3 million [12] - MACI revenue grew by 15% year-over-year, which adjusts to approximately 17% growth when accounting for one fewer selling day in the quarter [12] - NexoBrid revenue increased by 207% year-over-year and 31% sequentially [12] - The net loss for the quarter was $11.2 million, or $0.23 per share, with non-GAAP adjusted EBITDA of $3.2 million, representing 6% of net revenue [15] Business Line Data and Key Metrics Changes - MACI had a strong quarter with record revenue exceeding $46 million, driven by strong underlying fundamentals and a growing surgeon customer base [6] - NexoBrid revenue showed significant growth, indicating progress in its launch and deeper penetration in ordering centers [10] - Epicel revenue was lower than anticipated due to a high percentage of canceled cases related to patient health issues, despite the highest number of biopsies since 2023 [10][13] Market Data and Key Metrics Changes - The company expects total revenue growth of 22% to 25% for Q2 2025, with MACI revenue projected to be approximately $54 million [17] - The addressable market for MACI is estimated at 60,000 patients annually, with significant opportunities in treating femoral condyle and trochlear defects [24][25] Company Strategy and Development Direction - The company plans to expand its MACI sales force in the second half of 2025, driven by strong early indicators from the MACI Arthro launch [9][19] - The MACI Ankle Development Program is on track to initiate Phase III clinical studies, representing a substantial long-term growth driver with an estimated market of $1 billion [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about strong underlying MACI business fundamentals and early indicators from the MACI Arthro launch, suggesting potential for incremental growth [20] - The company reaffirmed its full-year revenue guidance of 20% to 23% growth and raised profitability guidance, expecting gross margins to reach 75% and adjusted EBITDA margins to 26% for the year [17] Other Important Information - The company ended the quarter with approximately $162 million in cash, restricted cash, and investments, with no debt [15] - Management noted that tariffs are expected to have a negligible impact on the business due to domestic manufacturing and significant safety stock [16] Q&A Session Summary Question: Can you discuss the market opportunity for femoral condyle and trochlear specifically? - Management indicated that the MACI Arthro instruments are designed for femoral condyle defects, representing a significant portion of the addressable market, and surgeons are also using them for trochlear defects, expanding the potential market [24][25] Question: How do you see seasonality and pacing for MACI in the second half of the year? - Management acknowledged that while MACI typically follows a seasonal pattern, strong leading indicators suggest potential for enhanced growth in the second half of the year [30][31] Question: What is the contribution of MACI Arthro to the first quarter numbers? - Management noted that while it is difficult to quantify the exact contribution from MACI Arthro in Q1, they expect a more significant impact in the second half of the year [36][37] Question: How are you prioritizing MACI Arthro training among surgeon groups? - Management explained that training occurs through industry events and individual sessions, focusing first on existing MACI users before targeting new surgeons [92][93] Question: How has the recent trade war impacted your view on MACI internationally? - Management stated that they are evaluating the potential for MACI outside the U.S. and will consider trade impacts before making decisions [90][91]

Novavax (NVAX) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good morning, and welcome to Novavax First Quarter twenty twenty five Financial Results and Operational Highlights Conference Call. All participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note, this event is being recorded. I'd now like to turn the conference over to Luis Sannai, Vice President, Investor Relations. Please go ahead. Speaker1 Good morning, and thank ...

Krispy Kreme (DNUT) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Hello, everyone, and thanks for standing by. My name is Ian, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Krispy Kreme First Quarter twenty twenty five Earnings Call. I would now like to turn the call over to Alexander Eldridge, Krispy Kreme Investor Relations. Please go ahead. Speaker1 Thank you. Good morning, everyone. Welcome to Krispy Kreme's first quarter twenty twenty five ear ...

Financial Data and Key Metrics Changes - Total revenue grew 22% year over year to $106.5 million in Q1 2025, driven by increased sales for VivGuard, Zejula, and NUZYRA [29][30] - Operating loss improved by 20% to $56.3 million, and adjusted loss from operations decreased by 25% to $37.1 million [16][30] - The company reaffirmed its full-year revenue guidance of $560 million to $590 million, anticipating significant sales growth in the latter part of the year [8][30] Business Line Data and Key Metrics Changes - VivGuard sales are expected to grow faster than total revenue growth, with a rebound in patient volumes observed in March and April after a seasonal decline [12][36] - Other products, including Zejula and NUZYRA, delivered sequential growth supported by NRDL access, with early contributions from OGTYRO and ZACDURO [15] - The company is preparing for upcoming NRDL cycles targeting IV renewal for gMG and initial listing of the SC formulation [14] Market Data and Key Metrics Changes - The company noted a significant opportunity in the gMG market in China, with approximately 70,000 patients, and less than 10% currently receiving newer biologic therapies [63] - The competitive landscape for gMG is expected to benefit from the introduction of new therapies, which will enhance overall market education and treatment options [63] Company Strategy and Development Direction - The company aims to expand its global R&D pipeline, with a focus on differentiated and high-potential assets, including GL1310 and other novel therapies [9][10] - Investments are being made to accelerate the global R&D pipeline, with plans to present updated Phase I data at ASCO [10][20] - The company is committed to achieving profitability by Q4 2025, leveraging operational efficiencies and a robust late-stage opportunity pipeline [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue targets and surpassing $2 billion by 2028, with strong momentum expected to carry into the 2030s [9] - The management team highlighted the importance of strategic initiatives to extend treatment duration and improve patient access [12][14] - The company remains optimistic about its financial position, ending Q1 with a cash position of $857.3 million [31] Other Important Information - The company is advancing its internal pipeline while also considering external opportunities for in-licensing [102][103] - Regulatory discussions with the FDA are ongoing, with no significant changes noted in the approval process despite recent leadership changes at the FDA [53][105] Q&A Session Summary Question: Can you provide more color on VIBGART's sequential change? - Management indicated that the sequential decline was influenced by seasonality and inventory dynamics, with confidence in recovery based on strong patient volumes in April [33][36] Question: Are you comfortable with consensus estimates for VIBGART and fiscal year revenues? - Management reaffirmed their revenue guidance and expressed confidence that VIBGART sales would grow faster than overall business rates [42][44] Question: How do recent FDA changes impact Zai Lab? - Management noted no anticipated impact from tariffs and indicated that FDA interactions have remained productive [50][53] Question: What is the competitive landscape for gMG in China? - Management believes that new approvals will benefit the market and enhance treatment options for patients [63] Question: What is the strategy regarding in-house developed assets? - The company plans to maintain a balanced approach between in-house development and external licensing opportunities [102][103]

Financial Data and Key Metrics Changes - Total revenue grew 22% year over year to $106.5 million in Q1 2025, driven by increased sales for VivGuard, Zejula, and NUZYRA [27] - Operating loss improved by 20% to $56.3 million, and adjusted loss from operations decreased by 25% to $37.1 million, reflecting operational efficiency [15][27] - The company reaffirmed its full-year revenue guidance of $560 million to $590 million, anticipating significant sales growth in the latter part of the year [6][28] Business Line Data and Key Metrics Changes - VivGuard sales are expected to grow faster than total revenue growth, with a rebound in patient volumes observed in March and April after a seasonal decline [11][12] - Other products, including Zejula and NUZYRA, showed sequential growth supported by NRDL access, with early contributions from newly launched products like OGTYRO and ZACDURO [14] - The company is preparing for the upcoming NRDL cycle targeting IV renewal for gMG and initial listing of the SC formulation, effective January 1, 2026 [12] Market Data and Key Metrics Changes - The company noted a significant opportunity in the gMG market in China, with approximately 70,000 patients, and less than 10% currently receiving newer biologic therapies [60] - The competitive landscape for gMG is expected to benefit from the introduction of new therapies, which will enhance overall market education and treatment options [60] Company Strategy and Development Direction - The company aims to expand its global R&D pipeline, with a focus on innovative therapies and maintaining a balanced approach between in-house development and business development opportunities [8][100] - Investments are being made to accelerate the global R&D pipeline, with a commitment to advancing at least one global product to IND submission stage every year [23] - The company is focused on achieving profitability by Q4 2025, leveraging operational efficiencies and a robust late-stage pipeline [15][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability by Q4 2025, citing strong business fundamentals and strategic direction [6][27] - The company anticipates accelerating sales growth in the next three quarters, which will translate into significant operating leverage [6] - Management highlighted the importance of new product launches and regulatory approvals in driving future growth [15][28] Other Important Information - The company ended the quarter with a strong cash position of $857.3 million, providing a solid foundation for future investments and growth initiatives [29] - The company is actively pursuing regulatory reviews for multiple products, including CAR XT for schizophrenia and TIVDAC for cervical cancer [15] Q&A Session Summary Question: Can you describe the sequential change in VIBGART sales? - Management indicated that the sequential decline was influenced by seasonal trends and inventory dynamics, with a strong recovery in patient volumes observed in March and April [31][32] Question: Are you comfortable with the current consensus for VIBGART and fiscal year revenues? - Management reaffirmed confidence in the revenue guidance range of $560 million to $590 million, indicating that VIBGART sales are expected to grow faster than overall sales growth [41] Question: How do recent FDA changes and tariffs impact Zai Lab? - Management noted no anticipated impact from tariffs, as local manufacturing is in place for many products, and FDA interactions have remained productive [46][50] Question: What is the competitive landscape for gMG in China? - Management expressed optimism about the competitive dynamics, stating that new approvals will benefit the overall market and enhance treatment options for patients [60] Question: What is the strategy regarding in-house developed assets versus in-licensing? - Management indicated a balanced approach, continuing to pursue both in-house development and high-quality external opportunities [100]